Valuation: Sutro Biopharma, Inc.

Market Cap 181M 161M 149M 136M 257M 17.22B 261M 1.8B 704M 8.98B 681M 666M 28.64B P/E 2026 *
-1.33x
P/E 2027 * -1.66x
Enterprise Value 181M 161M 149M 136M 257M 17.22B 261M 1.8B 704M 8.98B 681M 666M 28.64B EV / Sales 2026 *
3.52x
EV / Sales 2027 * 5.74x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 day-4.54%
1 week-23.34%
Current month-32.09%
1 month-29.33%
3 months-53.59%
6 months-65.32%
Current year-5.45%
1 week 10.36
Extreme 10.36
14.21
1 month 10.36
Extreme 10.36
16.66
Current year 10.15
Extreme 10.15
43.85
1 year 7.15
Extreme 7.15
43.85
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 13/03/2025
Director of Finance/CFO 53 02/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 70 01/08/2009
Director/Board Member 67 01/02/2017
Director/Board Member 51 25/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 A Exercice

Chief Technology Officer

8,845 0.0533%
6/2/26 A Exercice

Chief Financial Officer

5,000 0.0302%
3/4/26 A Exercice

Chief Administrative Officer

1,627 0.0099%
Change 5-day change 1-year change 3-year change Capi.($)
-4.54%-23.34%+8.32%-69.95% 181M
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -1.95%-2.65%+41.80%+77.89% 37.26B
Weighted average by Cap. -2.20%-0.51%+44.23%+96.45%

Financials

2026 *2027 *
Net sales 51.55M 45.83M 42.47M 38.64M 72.92M 4.89B 74.09M 511M 200M 2.55B 193M 189M 8.14B 31.59M 28.08M 26.03M 23.68M 44.69M 3B 45.4M 313M 123M 1.56B 119M 116M 4.99B
Net income -130M -115M -107M -97.09M -183M -12.29B -186M -1.28B -503M -6.41B -486M -476M -20.45B -141M -125M -116M -105M -199M -13.36B -202M -1.39B -546M -6.97B -528M -517M -22.22B
Net Debt - -
Projected Income Statement - Annual - Sutro Biopharma, Inc.
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Employees
128
Date Price Change Volume
16/10/26 $10.94 -4.54% 363,464
15/10/26 $11.46 +8.94% 418,381
14/10/26 $10.52 -4.45% 489,824
13/10/26 $11.01 -17.09% 406,676
12/10/26 $13.28 -6.94% 298,744
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Sutro Biopharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
10.94USD
Average target price
47.23USD
Spread / Average Target
+331.73%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sutro Biopharma, Inc.
  1. Stock Market
  2. Stocks
  3. STRO Stock